Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) have received an average rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $38.6667.
A number of research analysts have commented on the company. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Wall Street Zen cut Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Finally, Canaccord Genuity Group raised their price target on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd.
Get Our Latest Stock Analysis on Pharming Group
Pharming Group Price Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. As a group, equities analysts expect that Pharming Group will post 0.25 EPS for the current year.
Hedge Funds Weigh In On Pharming Group
Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group in the 2nd quarter worth about $32,000. SmartHarvest Portfolios LLC purchased a new stake in Pharming Group in the fourth quarter worth about $224,000. Millennium Management LLC bought a new position in shares of Pharming Group during the fourth quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC increased its stake in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares in the last quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.
Featured Stories
- Five stocks we like better than Pharming Group
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
